Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia.

Journal: Blood
Published Date:

Abstract

Although genomic alterations drive the pathogenesis of acute myeloid leukemia (AML), traditional classifications are largely based on morphology, and prototypic genetic founder lesions define only a small proportion of AML patients. The historical subdivision of primary/de novo AML and secondary AML has shown to variably correlate with genetic patterns. The combinatorial complexity and heterogeneity of AML genomic architecture may have thus far precluded genomic-based subclassification to identify distinct molecularly defined subtypes more reflective of shared pathogenesis. We integrated cytogenetic and gene sequencing data from a multicenter cohort of 6788 AML patients that were analyzed using standard and machine learning methods to generate a novel AML molecular subclassification with biologic correlates corresponding to underlying pathogenesis. Standard supervised analyses resulted in modest cross-validation accuracy when attempting to use molecular patterns to predict traditional pathomorphologic AML classifications. We performed unsupervised analysis by applying the Bayesian latent class method that identified 4 unique genomic clusters of distinct prognoses. Invariant genomic features driving each cluster were extracted and resulted in 97% cross-validation accuracy when used for genomic subclassification. Subclasses of AML defined by molecular signatures overlapped current pathomorphologic and clinically defined AML subtypes. We internally and externally validated our results and share an open-access molecular classification scheme for AML patients. Although the heterogeneity inherent in the genomic changes across nearly 7000 AML patients was too vast for traditional prediction methods, machine learning methods allowed for the definition of novel genomic AML subclasses, indicating that traditional pathomorphologic definitions may be less reflective of overlapping pathogenesis.

Authors

  • Hassan Awada
    Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Arda Durmaz
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Carmelo Gurnari
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Ashwin Kishtagari
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Manja Meggendorfer
    Munich Leukemia Laboratory, Munich, Germany.
  • Cassandra M Kerr
    Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Teodora Kuzmanovic
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Jibran Durrani
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Jacob Shreve
    Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
  • Yasunobu Nagata
    Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Tomas Radivoyevitch
    Department of Quantitative Health Sciences and.
  • Anjali S Advani
    Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Farhad Ravandi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hetty E Carraway
    Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Aziz Nazha
    Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, United States; Department of Hematology and Medical Oncology, Cleveland Clinic, United States; Center for Clinical Artificial Intelligence, Cleveland Clinic, United States. Electronic address: nazhaa@ccf.org.
  • Claudia Haferlach
    MLL Munich Leukemia Laboratory, Munich, Germany.
  • Yogen Saunthararajah
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Jacob Scott
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Valeria Visconte
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Hagop Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston.
  • Tapan Kadia
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; and.
  • Mikkael A Sekeres
    Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH; and.
  • Torsten Haferlach
    MLL Munich Leukemia Laboratory, Munich, Germany.
  • Jaroslaw P Maciejewski
    Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.